Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Devi Nampiaparampil

Interventional Pain Medicine New York, NY Medical Doctor

NPI 1205982501 CMS profile 711412

111 John Street, Suite 2509, New York, NY 10038

Open in the dashboard

General payments

$18,297

98 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Devi Nampiaparampil of New York, NY is reported in the CMS Open Payments database as having received $18,297 across 98 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40 2
2024 General $283 4
2023 General $158 9
2022 General $2,219 20
2021 General $7,999 17
2020 General $5,489 20
2019 General $2,109 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Devi Nampiaparampil
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Devi Nampiaparampil were reported at $40. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Devi Nampiaparampil Interventional Pain Medicine median Middle half National median
2019 $2,109 $684 $216–$2,079 $163
2020 $5,489 $382 $122–$1,109 $114
2021 $7,999 $552 $167–$1,554 $132
2022 $2,219 $605 $187–$1,924 $149
2023 $158 $671 $195–$1,915 $160
2024 $283 $684 $206–$1,837 $164
2025 $40 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $7,191 19 payments
  2. AbbVie, Inc. $6,573 30 payments
  3. Biohaven Pharmaceuticals, Inc. $1,200 1 payment
  4. Bioventus LLC $1,129 7 payments
  5. Neuronetics, Inc. $410 3 payments
  6. Amgen Inc. $358 9 payments
  7. Teva Pharmaceuticals USA, Inc. $281 4 payments
  8. Flowonix Medical Incorporated $191 1 payment
  9. SI-BONE, Inc. $151 2 payments
  10. Boston Scientific Corporation $144 1 payment
  11. Other $669 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,940 10 payments
  2. Food and Beverage $3,220 79 payments
  3. Consulting Fee $1,200 1 payment
  4. Travel and Lodging $866 3 payments
  5. Education $71 5 payments
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $8,091 17 payments
  2. UBRELVY Neuroscience $5,356 11 payments
  3. NURTEC ODT $1,233 3 payments
  4. Durolane $1,115 6 payments
  5. AIMOVIG $358 9 payments
  6. NEUROSTAR TMS THERAPY SYSTEM $356 2 payments
  7. Ajovy $281 4 payments
  8. Prometra II $191 1 payment
  9. IFUSE IMPLANT $151 2 payments
  10. QULIPTA $150 8 payments
  11. Other $1,160 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

69

Median for Interventional Pain Management: 1,220

Drug cost

$1,480

Median for Interventional Pain Management: $39,344

Branded share of claims

0%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 31 $1,130
Tramadol Hcl Generic 12 $251
Pregabalin Generic 11 $68
Topiramate Generic 15 $31

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $26
$26 — —
QULIPTA
  • AbbVie, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record